TL;DR
This study reveals that reduced levels of 5-hydroxymethylcytosine (5hmC), an epigenetic mark, are a hallmark of pediatric posterior fossa ependymoma (EPN_PF). Crucially, lower 5hmC levels are associated with a poorer prognosis, suggesting 5hmC could serve as a valuable biomarker for predicting patient outcomes.
What Problem Does This Paper Address?
Ependymoma (EPN) is a significant brain tumor in children, with posterior fossa EPN (EPN_PF) being particularly challenging. While EPN_PF is known to have distinct molecular subgroups (EPN_PFA and EPN_PFB) with different prognoses, the underlying epigenetic mechanisms driving these differences and influencing patient outcomes remain largely unclear. Specifically, the role of 5-hydroxymethylcytosine (5hmC), a modified form of DNA methylation, in EPN_PF pathogenesis and its potential as a prognostic indicator were not well understood. This paper aims to characterize global 5hmC levels in pediatric EPN_PF, compare them to normal brain tissue, and investigate their correlation with molecular subgroups, cell proliferation markers, and clinical outcomes.
Methods
The researchers employed a multi-pronged approach:
- UHPLC-MS/MS (Ultra-High-Performance Liquid Chromatography-Mass Spectrometry): This technique was used to quantify the global levels of 5hmC and its precursor, 5-methylcytosine (5mC), in tumor samples and normal cerebellum tissues. This is a standard method for precise molecular quantification.
- Immunohistochemistry (IHC): IHC was used to visualize the presence and distribution of 5hmC and Ki-67 (a marker of cell proliferation) within the tumor tissues. This provides spatial information about these molecules. They also used IHC to classify EPN subtypes based on H3K27me3 staining, a known method for distinguishing EPN_PFA from EPN_PFB.
- Fluorescence In Situ Hybridization (FISH): FISH was used to detect gains in chromosome 1q, a known genetic alteration associated with EPN_PF.
- Statistical Analysis: A range of statistical methods were used, including Mann-Whitney U tests and Student's t-tests for comparing group means, Pearson correlation for assessing relationships between variables, and multivariate Cox proportional hazards regression models to identify independent prognostic factors for survival.
Datasets
The study utilized a cohort of 45 pediatric posterior fossa ependymoma (EPN_PF) patients diagnosed at Beijing Tiantan Hospital between January 2010 and December 2017. Nine normal cerebellum samples were used as controls. Clinical data, including age, gender, tumor size, surgical extent, radiotherapy and chemotherapy use, histology (WHO grades II/III), molecular subgroup (EPN_PFA/EPN_PFB), 1q gain status, recurrence, and survival outcomes, were collected retrospectively.
Key Insights and Ideas
- 5hmC as a "Sixth Base" in Cancer Epigenetics: The study reinforces the growing understanding of 5hmC not just as a passive byproduct of DNA demethylation but as an active epigenetic mark with functional implications in cancer.
- Loss of 5hmC in EPN_PF: The consistent finding of decreased 5hmC in tumor tissues compared to normal brain tissue is a significant observation, suggesting that this epigenetic modification is actively lost during tumorigenesis in this specific cancer type.
- Molecular Subgroup Specificity: The differential levels of 5hmC between EPN_PFA and EPN_PFB subgroups highlight that epigenetic alterations are not uniform across all EPN_PF subtypes and may contribute to their distinct clinical behaviors.
- 5hmC and Proliferation Link: The positive correlation between 5hmC levels and Ki-67 index is intriguing. While counterintuitive to some findings in other cancers where reduced 5hmC might be linked to proliferation, it suggests a specific role for 5hmC in EPN_PF cell growth.
- Prognostic Power of 5hmC: The most impactful insight is the demonstration that 5hmC levels can independently predict patient prognosis (progression-free survival and overall survival). This opens the door for its use as a clinical biomarker.
Key Results
- Global 5hmC Reduction: Pediatric EPN_PF tumors showed significantly lower global 5hmC levels compared to normal cerebellum tissues (P < 0.001).
- Subgroup Differences: EPN_PFA tumors exhibited higher 5hmC levels than EPN_PFB tumors (P = 0.007).
- Correlation with Ki-67: 5hmC levels positively correlated with the Ki-67 proliferation index (r = 0.428, P = 0.003).
- Prognostic Significance: Patients with high 5hmC levels (> 0.102%) had significantly worse progression-free survival (PFS) and overall survival (OS) compared to those with low 5hmC levels (< 0.102%) (PFS: HR = 3.014, P = 0.042; OS: HR = 2.788, P = 0.047).
- Independent Predictor: In multivariate analysis, 5hmC subgroup (high vs. low) was confirmed as an independent predictor of worse PFS and OS.
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Size: The study included 45 patients, which is considered a relatively small sample size, potentially limiting the power to detect subtle associations and requiring validation in larger cohorts.
- Short Follow-up Period: The median follow-up period of 38 months, while substantial, might not be long enough to capture all long-term outcomes.
- IHC for Subgroup Classification: Molecular subgrouping was primarily based on IHC, which can be less precise than molecular methods. Future studies using fresh frozen tissues and methylation arrays are suggested for more robust classification.
Future work should focus on:
- Mechanism of 5hmC Influence: Further research is needed to elucidate the precise mechanisms by which 5hmC influences EPN_PF cell proliferation and tumorigenesis.
- Therapeutic Targeting: Given the role of 5hmC in EPN_PF, targeting the pathways regulating its levels could represent a novel therapeutic strategy.
- Validation in Larger Cohorts: Confirming these findings in larger, independent patient cohorts is crucial for establishing 5hmC as a reliable clinical biomarker.
Summary updated